ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2520

Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World

Michelle Teo1, Derek Haaland2, John Kelsall3, Isabelle Fortin4, Pauline Boulos5, Raman Rai6, Sanjay Dixit7, B Haraoui8, Dalton Sholter9, Eliofotisti Psaradellis10, Emmanouil Rampakakis10, Brendan Osborne11, Francois Nantel11 and Allen J Lehman12, 1Balfour Medical Clinic, Penticton, BC, Canada, 2Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, 3Rheumatology, University of British Columbia, Vancouver, BC, Canada, 4Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, 5Rheumatology, McMaster University, Hamilton, ON, Canada, 6Private Practice, Hamilton, ON, Canada, 7Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, 8Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 9Rheumatology Associates, Edmonton, AB, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Ankylosing spondylitis (AS), Biologics, extraarticular manifestations, psoriatic arthritis and registry

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 7, 2017

Session Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Spondyloarthropathies (SpA) encompass a heterogeneous group of chronic inflammatory diseases affecting axial and peripheral joints. Besides articular symptoms, patients also experience extra-articular manifestations (EAMs) including uveitis, psoriasis, inflammatory bowel disease (IBD) and multiple organ involvement. The aim of this analysis was to describe the incidence of new onset EAMs focusing on uveitis and IBD among SpA pts over 6 and 12 months of treatment with golimumab (GLM).

Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment with infliximab or GLM for RA, AS, or PsA, or with ustekinumab for PsA. Eligible participants for this analysis comprised GLM-treated AS (n=395) and PsA (n=257) patients. Presence of EAMs was defined as patients with uveitis or IBD.  IBD data, however, was not collected for PsA pts.  Results were based on patients with available data. Safety was ascertained by the incidence of adverse events (AEs) and serious adverse events (SAEs), reported per 100 pt years (PY) of follow-up.

Results: Among AS pts, at baseline, the mean (SD) age was 45.3 (13.5) years and CRP was 14.1 (30.5) mg/L. Positive HLA B27 status was reported for 174 (174/264; 65.9%) pts. History of uveitis was reported among 14.2% (n=50/352) of AS pts. EAMs are reported over time in Table 1. New-onset uveitis and IBD was reported for 2.3% (3.2 events/100 PY) and 1.1% (1.5 events/100 PY) of pts during follow-up, respectively. Results showed that CRP and HLA B27 status were not significantly associated with presence of EAMs at baseline. Overall, 419 AEs and 26 SAEs were reported by 199 (50.4%) and 16 (4.1%) pts by 12 months of treatment, respectively, for a total of 144.1 AEs/100 PY and 8.9 SAEs/100 PY.  A total of 5 AEs of uveitis were reported all of which were of mild severity, and either not (n=4) or unlikely related (n=1) to the study drug.

Among PsA pts, the mean (SD) age was 52.7 (13.2) years and CRP was 13.2 (32.4) mg/L at baseline. A total of 9 (9/80; 11.3%) pts had positive HLA B27 status. Patients with a history of uveitis was reported for 1.8% (n=4/224) of PsA pts. New-onset uveitis was reported for 0.4% (0.5 events/100 PY) of patients during follow-up. Overall, 254 AEs and 15 SAEs were reported by 123 (47.9%) and 12 (4.7%) patients by 12 months of treatment, respectively, for a total of 135.0 AEs/100 PY and 8.0 SAEs/100 PY. 

Table 1. EAMs over Time and New Onset since Baseline

Diagnosis

EAM

Patients with EAMs

n/N

New Onset at 6 Months

New Onset at 12 Months

New Onset over Follow-up¥

Baseline

6 Months

12 Months

n/N*

n/N*

n/N

AS

Uveitis

4/390

8/278

1/197

8/272

1/189

9/386

No uveitis

386/390

270/278

196/197

NA

NA

NA

IBD

22/393

16/277

10/195

4/256

0/184

4/371

No IBD

371/393

261/277

185/195

NA

NA

NA

PsA

Uveitis

0/256

1/187

0/131

1/186

NA

1/256

No uveitis

256/256

186/187

131/131

NA

NA

NA

Patients with unknown EAM were excluded from the analysis. *Denominator (N) represents patients at risk at the respective visit relative to the previous visit. ¥Average follow-up per patient was 8.8 months for AS and 9.8 months for PsA. NA=not applicable

Conclusion: In patients with AS, development of uveitis and IBD was 2.3% and 1.1% during 12-month follow-up of GLM-treatment. Among PsA patients, lower rates of new-onset uveitis were observed with 0.4%. The current results should be interpreted with caution given the low number of cases of uveitis and IBD.

 

 

 

 

 

 

 

 

 

 


Disclosure: M. Teo, None; D. Haaland, None; J. Kelsall, None; I. Fortin, None; P. Boulos, None; R. Rai, None; S. Dixit, None; B. Haraoui, None; D. Sholter, None; E. Psaradellis, Janssen Inc., 9; E. Rampakakis, Janssen Inc., 9; B. Osborne, Janssen Inc., 3; F. Nantel, Janssen Inc., 3; A. J. Lehman, Janssen Inc., 3.

To cite this abstract in AMA style:

Teo M, Haaland D, Kelsall J, Fortin I, Boulos P, Rai R, Dixit S, Haraoui B, Sholter D, Psaradellis E, Rampakakis E, Osborne B, Nantel F, Lehman AJ. Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/incidence-of-extra-articular-manifestations-in-psa-and-as-patients-treated-with-golimumab-in-canadian-real-world/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-extra-articular-manifestations-in-psa-and-as-patients-treated-with-golimumab-in-canadian-real-world/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.